Dec 30, 2025 • Finviz
SOMEWHAT-BULLISH
Abbott (ABT) Wins FDA Approval for Volt PFA System in AFib Treatment
Abbott Laboratories (ABT) has received FDA approval for its Volt™ PFA System, designed to treat patients with atrial fibrillation (AFib). This system will soon be commercially available in the U.S. and is already expanding in the EU after CE Mark approval. The approval follows the VOLT-AF IDE study, which demonstrated the system's safety and effectiveness for both paroxysmal and persistent AFib.
Dec 29, 2025 • openPR.com
BULLISH
The Future of Bone Sonometer Market 2032 Industry Forecast
The Bone Sonometer Market is projected to grow from USD 1,336.8 Mn in 2025 to USD 1,996.8 Mn by 2032, exhibiting a CAGR of 5.9%. This growth is driven by rising industry demand, expanding applications, and technological advancements, according to a report by Coherent Market Insights. The report provides a comprehensive analysis of market drivers, restraints, opportunities, and competitive landscape, with a detailed regional assessment to inform strategic business decisions.
Dec 29, 2025 • openPR.com
SOMEWHAT-BULLISH
Skin Rejuvenation Devices Market Forecast Report: Strategic Insights, Expansion Opportunities and Key Players to 2032 |Cutera Inc., Hologic, Inc., Lutronic Corporation
The global skin rejuvenation devices market is projected to grow from US$2,227.4 million in 2022 to exhibit a CAGR of 9.5% during 2022-2030, driven by rapid innovation and shifting regional dynamics. This report offers strategic insights, segmentation by type, application, and region, and profiles key industry players like Cutera Inc. and Hologic Inc. It also highlights investment hotspots and production/consumption patterns to help stakeholders capitalize on upcoming opportunities.
Dec 28, 2025 • Yahoo Finance
NEUTRAL
Why a $7.3 Million Bet on Core Scientific Looked Smart at Quarter-End but Got Tested 30% Later
PSquared Asset Management initiated a significant $7.28 million stake in Core Scientific during the third quarter of 2025, betting on its stabilizing digital infrastructure and potential merger with CoreWeave. However, the stock price faced a 30% decline after the merger agreement was terminated due to shareholder disapproval. Despite this setback, Core Scientific still possesses valuable power infrastructure and is shifting its focus towards hosting and AI-adjacent workloads.
Dec 28, 2025 • The Globe and Mail
NEUTRAL
Why a $7.3 Million Bet on Core Scientific Looked Smart at Quarter-End but Got Tested 30% Later
PSquared Asset Management initiated a significant position in Core Scientific during the third quarter, which initially appeared to be a smart move due to the company's stabilizing digital infrastructure and potential merger. However, Core Scientific's stock price dropped by nearly 30% after the termination of its merger agreement with CoreWeave, raising questions about execution risk. Despite the stock plunge, the underlying operational shift towards hosting and compute services utilizing valuable power infrastructure remains.
Dec 25, 2025 • TradingView — Track All Markets
SOMEWHAT-BULLISH
Spotting Winners: Hologic (NASDAQ:HOLX) And Medical Devices & Supplies - Imaging, Diagnostics Stocks In Q3
This article reviews the Q3 earnings for medical devices & supplies - imaging, diagnostics stocks, highlighting Hologic (NASDAQ:HOLX), QuidelOrtho (QDEL), GE HealthCare (GEHC), and Lantheus (LNTH). The industry faces challenges like high development costs and regulatory hurdles but benefits from consistent demand and technological advancements. Hologic showed strong revenue growth, QuidelOrtho outperformed expectations with a guidance raise, GE HealthCare had good results despite being the "weakest," and Lantheus beat analyst estimates significantly.